Abstract
Chemoradiation is the major treatment option in unresectable, locally advanced non-small cell lung cancer. Many clinical trials have evaluated the efficacy of different combinations of chemotherapy and radiotherapy in this heterogeneous patient population. Early clinical trials showed a survival advantage of sequential chemo-RT compared to radiation alone. Subsequent trials demonstrated that concurrent chemo-RT improved survival over sequential chemo-RT. More recent studies have suggested that there is no advantage to adding induction chemotherapy prior to concurrent chemo-RT, or to adding consolidation chemotherapy after concurrent chemo-RT. Various clinical trials have used different chemotherapy regimens, though there is still no consensus about those which are most effective. Additionally, different radiotherapeutic strategies have included hyperfractionation vs. standard fractionation, use of 3-dimensional techniques, and altering total radiation dose. As these methods are being perfected, much attention has turned toward the use of molecularly targeted therapies. This review summarizes recent clinical trials examining the role of chemo-RT in locally advanced non-small cell lung cancer and the movement toward personalized medicine.
Keywords: Locally advanced NSCLC, chemoradiation, molecularly targeted therapy
Reviews on Recent Clinical Trials
Title: Chemoradiotherapy in Locally Advanced, Unresectable Non-Small Cell Lung Cancer
Volume: 4 Issue: 2
Author(s): Lauren R. Mitchell, Jeffrey M. Albert and Bo Lu
Affiliation:
Keywords: Locally advanced NSCLC, chemoradiation, molecularly targeted therapy
Abstract: Chemoradiation is the major treatment option in unresectable, locally advanced non-small cell lung cancer. Many clinical trials have evaluated the efficacy of different combinations of chemotherapy and radiotherapy in this heterogeneous patient population. Early clinical trials showed a survival advantage of sequential chemo-RT compared to radiation alone. Subsequent trials demonstrated that concurrent chemo-RT improved survival over sequential chemo-RT. More recent studies have suggested that there is no advantage to adding induction chemotherapy prior to concurrent chemo-RT, or to adding consolidation chemotherapy after concurrent chemo-RT. Various clinical trials have used different chemotherapy regimens, though there is still no consensus about those which are most effective. Additionally, different radiotherapeutic strategies have included hyperfractionation vs. standard fractionation, use of 3-dimensional techniques, and altering total radiation dose. As these methods are being perfected, much attention has turned toward the use of molecularly targeted therapies. This review summarizes recent clinical trials examining the role of chemo-RT in locally advanced non-small cell lung cancer and the movement toward personalized medicine.
Export Options
About this article
Cite this article as:
Mitchell R. Lauren, Albert M. Jeffrey and Lu Bo, Chemoradiotherapy in Locally Advanced, Unresectable Non-Small Cell Lung Cancer, Reviews on Recent Clinical Trials 2009; 4 (2) . https://dx.doi.org/10.2174/157488709788185969
DOI https://dx.doi.org/10.2174/157488709788185969 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Arsenic trioxide Alters the MicroRNA Expression Profile of U87 glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis
Current Pharmaceutical Design Radiolabelled Peptides and Monoclonal Antibodies for Therapy Decision Making in Inflammatory Diseases
Current Pharmaceutical Design Engineering Approaches to Develop the Next Generation of Antibodies to Respiratory Targets
Inflammation & Allergy - Drug Targets (Discontinued) Imaging of HER-2 Overexpression in Tumors for Guiding Therapy
Current Pharmaceutical Design HIV-1 Tat-Mediated Calcium Dysregulation and Neuronal Dysfunction in Vulnerable Brain Regions
Current Drug Targets Targeted Drug Delivery Using Tuftsin-bearing Liposomes: Implications in the Treatment of Infectious Diseases and Tumors
Current Drug Targets Bioactivity of Chitosan and Its Derivatives
Current Organic Chemistry Preclinical and Clinical Studies on Bryostatins, A Class of Marine-Derived Protein Kinase C Modulators: A Mini-Review
Current Topics in Medicinal Chemistry Mitochondrial Superoxide Dismutase: A Promising Target for New Anticancer Therapies
Current Medicinal Chemistry Anti-Cancer Natural Product Library from Traditional Chinese Medicine
Combinatorial Chemistry & High Throughput Screening Telomere Maintenance as Therapeutic Target in Embryonal Tumours
Anti-Cancer Agents in Medicinal Chemistry Methacholin Provocation Test in COPD and Healthy Smokers
Current Respiratory Medicine Reviews Adeno-Associated Virus-Mediated Gene Transfer in Hematopoietic Stem/Progenitor Cells as a Therapeutic Tool
Current Gene Therapy Talazoparib Loaded Solid Lipid Nanoparticles: Preparation, Characterization and Evaluation of the Therapeutic Efficacy In vitro
Current Drug Delivery Xenobiotic-Metabolizing Enzymes in Human Lung
Current Drug Metabolism The Orvinols and Related Opioids - High Affinity Ligands with Diverse Efficacy Profiles
Current Pharmaceutical Design Therapeutic Benefit and Biological Importance of Ginkgetin in the Medicine: Medicinal Importance, Pharmacological Activities and Analytical Aspects
Current Bioactive Compounds Hypoxia-Inducible Factor (HIF): Fuel for Cancer Progression
Current Molecular Pharmacology Decreasing the Metastatic Potential in Cancers - Targeting the Heparan Sulfate Proteoglycans
Current Drug Targets